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Abstract 
Ellipticine (EPT), a natural plant polyphenolic compound, has long been known for its 
significant anticancer and anti-HIV activities. Recent study on its photophysical properties 
has revealed that ellipticine has three molecular states: protonated, neutral and crystalline. 
Further in vitro cytotoxicity tests indicated that protonated ellipticine exhibited much higher 
anticancer activity than the other two states. To maximize drug therapeutic effect, a small 
library of ariginine-rich ionic complementary peptides derived from EAK, including 
EAR8-II, EAR8-a, ELR8-a, and EAR16-II, were investigated as a potential carrier to deliver 
prescribed protonated ellipticine for treatment of cancer. Fluorescence study demonstrated 
that all four peptides were able to solubilize and stabilize protonated ellipticine in aqueous 
solution at 5:1 mass ratio of peptide-to-ellipticine (0.5: 0.1 mg/mL) even upon 4000 times 
dilution. Physicochemical characteristics of peptides self-assemblies and peptide-ellipticine 
complexes such as particle size, surface charge, secondary structure and morphology were 
determined by dynamic light scattering (DLS), zeta potential, circular dichroism (CD) , 
atomic force microscopy (AFM) and transmission electron microscopy (TEM), respectively. 
Then the ellipticine maximum suspension was determined by ellipticine UV-absorption. 
With the help of the peptides and mechanical stirring overtime, up to 100% ellipticine could 
be uptaken and stabilized in the solution as protonated ellipticine. In vitro cytotoxicity tests 
indicated that the peptides were demonstrating significant biocompatibility without affecting 
the survival of two cancer cell lines, human lung carcinoma cell line A549 and  breast 
cancer cell line MCF-7, whereas the complexes with protonated ellipticine were found to 
show great anticancer activity to the two cancer cell lines. The IC50 values were obtained for 
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each of four different peptide-ellipticine complexes ranged from 0.36±0.12 to 18.90±0.46  M. 
It is worth noting that the IC50 value of EAR16-ellipticine complex to MCF-7 was over 50 
times higher than that one to A549, which presented that EAR16-ellipticine complex has a 
selective targeting activity to A549, with the lowest IC50 value of 0.36±0.12  M among all 
four complexes. Such a result indicated that this library of novel arginine-rich ionic 
complementary peptides had a great potential to encapsulate prescribed protonated ellipticine 
and exhibited an excellent anticancer activity upon serial dilution in aqueous solution. 
Overall, the charge distribution and increased hydrophobicity of the short (8 amino acids 
length) peptides seemed not to affect the complex formation and its therapeutic efficacy in 
vitro; however, the increase in length of the peptides significantly altered the nanostructure 
of peptides and its complexation with ellipticine, increased the therapeutic efficacy of 
EAR16-EPT to A549. This work provides essential information for peptide sequence design 
in the development of self-assembling peptide-based delivery of hydrophobic anticancer 
drugs.  
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Chapter 1 
Introduction  
1.1 Overview  
Over the past half century, cancer remains one of the major public health problems in 
North America
1
. As the second leading cause of death in the world after cardiovascular and 
cerebrovascular diseases, an average of 21 people was diagnosed with some kind of cancer 
per every hour of every day, and nine people died from cancer in Canada in 2012
2
. Cancer is 
a class of diseases sharing one important characteristic: loss of control of the normal cell 
cycle processes
3,4
. That is, cancer develops from changes that disrupt the normal functions of 
cell growth and reproduction. These changes often result from inherited mutations or are 
induced by environmental factors like chemicals, tobacco products, viruses, UV light and 
X-rays
5
. As a result of these mutations, cancer cells obtain new characteristics such as 
limitless proliferation potential, decreased cell adhesion, resistance to growth-inhibitory 
signals, as well as spread and invade other normal tissues.  
To date, surgery, radiotherapy and chemotherapy remain the most common therapies in 
the fight against cancer
6,7
. Even though many advances have been achieved in conventional 
treatments, these methods are limited by several drawbacks
8
, such as lack of selectivity, not 
just killing cancer cells, but also inhibiting the normal grow process of healthy cells, and 
cause low white blood cell count, gastrointestinal distress and hair loss. On the other hand, 
most anti-cancer drugs are very hydrophobic and have poor bioavailability, larger than 
enough drug doses are demanded, which lead to even higher toxicity to normal cells, along 
with an increased incidence of multiple drug resistance
9
.  
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Over the past two decades, the field of novel drug delivery system has evolved due to 
the slow progress in the diagnosis and treatment of severe diseases at the cellular level. 
Recent interest has been focusing on developing nanoscale delivery carriers capable of 
controlling the release of encapsulated chemotherapeutic drugs directly into cancer cells and 
cellular compartments
10, 11, 12
. This new strategy for the practice of medicine provides a more 
efficient solution to overcome the limitations existed in conventional anticancer therapy as 
discussed above.  
The main considerations when designing nanoscale delivery carriers are to prolong drug 
circulation time, improve membrane permeation, increase cell targeting capabilities and 
reduce cytotoxic effects on normal human cells
12, 13
. Up to now, several classes of materials 
have been developed, including liposomes
14,15
, polymeric nanoparticles
16,17
, dendrimer
18,19,20
, 
and self-assembly peptides
21,22
 incorporating cytotoxic therapeutics; some of them are 
already on the market and others are under clinical and preclinical research
19
.  
Self-assembling peptides are of interest for various biomedical applications because of 
their favorable properties, such as biodegradable, inherent biocompatibility, cell targeting, 
cell penetration and simplicity in producing a variety of nanostructures
23,24,25
. These peptides 
can assemble into well-ordered nanostructures by van der waals interaction, hydrogen 
bonding or hydrophobic interaction, which can withstand high temperatures, extreme pHs, 
and high concentrations of electrolyte
26
. Moreover, they exhibit good biocompatibility with 
many cultured mammalian cells and no detectable immune responses can be observed when 
introduced into animals
27
. As a result, self-assembling peptides are ideal nanomaterials for 
tissue engineering, regenerative medicine and controlled drug delivery system
28,29
. The 
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family of EAK16s is probably the most commonly studied class of self-assembling 
ionic-complementary peptides in drug delivery research. They are discovered from a yeast 
Z-DNA binding protein by Dr. Wang in the early 1990s
30
. These peptides feature a unique 
amphiphilic structure consisting of alternating hydrophilic and hydrophobic amino acids in 
the sequence, where the hydrophilic residues form alternating positive and negative charges, 
resulting in a complementary ionic structure
22
. It is known these EAK16s are able to form 
stable β-sheet structure in aqueous solution to provide a protected and stable environment for 
hydrophobic anticancer drugs ellipticine (EPT) in aqueous solution
21
. In vitro studies have 
also shown that the EAK-EPT complex exhibit anti-cancer activity at killing both MCF-7 
and A549 cells.  
Ellipticine (5, 11-dimethyl-6H-pyrido [4, 3-b] carbazole), a natural plant alkaloid, has 
long been known for its significant anticancer and anti-HIV activities
31
. Studies have showed 
its high efficiency against several types of cancer, including leukemias, melanoma, breast 
cancer, sarcomas, lung cancer cells and neuroblastomas
31,32
. Although the potential of EPT as 
an anticancer drug was discovered fifty years ago, its poor aqueous solubility, severe side 
effects and low bioavailability constituted major obstacles toward its medical deployment
33
. 
In recent years, several effective drug delivery vehicles have been developed, such as 
polymer
17,34
, micelles
35
 and peptides
21,36
 to improve clinical applicability of EPT, as well as 
other hydrophobic drugs
37,38
. Our previous studies have shown that EAKs peptide could be a 
potential vehicle to encapsulate EPT in three different molecular states: neutral form, EPT 
crystals and protonated EPT
21
. Meanwhile, it was found that the molecular states of EPT 
have great effect on the release kinetics of EPT from the peptide-EPT complex to EPC 
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vesicles. In more recent work, we first proposed that the different molecular states of EPT in 
the peptide-EPT complex would possess different drug efficacies in therapy
39
. In vitro 
studies indicated that complexes with protonated EPT had much higher toxicity than 
complexes with crystalline EPT against cancer cells. Studies in living cells also revealed that 
only protonated EPT can exist in the nucleus
32
. In order to maximize drug therapeutic effects, 
it is necessary to develop new drug carriers that can deliver a drug with a prescribed 
molecular state. However, much of research work on EPT delivery system is focused on 
creating hydrophobic carrier to encapsulate neutral EPT; very few studies have been 
performed on this special issue. 
In the first part of this research, I first elucidated the basic design principles for 
investigating a small library of model peptides that can self-assemble in aqueous solution to 
encapsulate particular protonated EPT. The self-assembly capability of these peptides were 
characterized by Axisymmetric Drop Shape Analysis-Profile (ADSA-P) technique and 
1-anilino-8-naphthalene sulfonate (ANS) fluorescence assay. Then I explored the potential of 
these peptides in drug delivery application, the fluorescence technique was utilized to 
characterize the molecular state of EPT in the complex to see if the prescribed protonated 
EPT could be encapsulated in the peptide self-assemblies. In the second part, we studied the 
effect of peptide length, sequence and hydrophobicity on the formation of peptide-EPT 
complexes in aqueous solution. The peptide and their complexes with EPT are studied in 
details for its secondary structures, morphology, particle size distribution and surface charge. 
The third part of this research was considered for the anticancer activity of the peptide-EPT 
complexes tested in vitro against two cancer cell lines: non-small cell lung cancer cell A549 
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and breast cancer cell MCF-7. The stability of the complexes after serial dilutions in aqueous 
solution was further investigated in relation to anticancer activity. The information obtained 
in this study is aimed at providing appropriate design principles for selecting peptide 
sequences, to construct advanced functional peptide carriers for anticancer drug delivery. 
1.2 Research objectives 
The goal of this research is to design a small library of model self-assembling ionic 
complementary peptides, which can self-assemble in aqueous solution to encapsulate 
particular protonated EPT and stabilized them for a long time. The specific objectives of this 
research study are listed as following:  
(1) Basic design principals of arginine-rich ionic complementary peptides as drug delivery 
system.  
(2) Study the surface tension properties of peptides and their potential to encapsulate 
protonated EPT. 
(3) Investigate the effect of length, charge distribution and hydrophobicity on the 
physicochemical properties of peptide assemblies and peptide-EPT complexation. 
(4) Evaluate the anticancer activity of peptide-EPT complexes and their dilutions in vitro. 
1.3 Outline of the thesis 
This thesis consists of five chapters as below:  
Chapter 1 gives an overview of the thesis, including a brief introduction to cancer 
statistics, cancer therapy, self-assembling peptides as a potential carrier in drug delivery. The 
objective of the research is given in this chapter. 
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Chapter 2 reviews the literature about properties of cancer, traditional cancer therapy, 
novel drug delivery systems and application of self-assembling ionic-complementary 
peptides as hydrophobic anticancer drug carrier.  
Chapter 3 presents the required material and experimental methods in detail for this 
research. 
Chapter 4 reports the results and discussion based on each research objective.   
Chapter 5 presents the conclusion of studies in the thesis and recommendations for 
future work. 
 
. 
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Chapter 2  
Literature Review 
2.1 Cancer and Cancer Therapy  
2.1.1 Introduction  
Cancer is one of the most serious health problems world-wide and is responsible for 
approximately 13% of all deaths, according to the World Health Organization
1
. In Canada 
alone, an estimated 186,400 new cases of cancer (excluding 81,300 non-melanoma skin 
cancers) and 75,700 deaths from cancer in 2012 was reported by The National Canadian 
Statistics
2
. Although prognosis is better now, the large variety of cancer types and metastases 
makes treatment very difficult
40
. Cancer is a disease in which the control of growth is lost in 
one or more cells, leading to an abnormal tissue mass of cells known as a tumor
41
. In the 
early stages of tumor growth, cancer cells often resemble the original cells; however, they 
can lose their appearance and function of their origin at a later stage. The rate of cancerous 
cells outgrows normally controlled cell populations and form a tumor mass. Studies show 
that the genetic changes that promote the progressive transformation of healthy cells at many 
different sites into tumor cells
42
. Tumor formation may result from changes to DNA 
sequence or structure by internal factors, such as mutations, addition or loss of DNA, or 
epigenetic changes. While external factors like viruses, bacterial infections, chemicals, or 
radioactivity can also lead to tumorigenesis
5
.  
Cancer treatment comprises more than one approach, and the strategy adopted depends 
on the nature of the cancer and how far it has progressed. Currently, the main treatments are 
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radiotherapy
7
, chemotherapy
6
 and surgery. However, other approaches such as photodynamic 
therapy
43
, antibody- and vaccine related approaches
44
, and gene therapy are in development.  
2.1.2 Properties of Cancer 
Cancer cells are abnormal cells in which the processes regulating normal cell cycle are 
disrupted; therefore, they no longer require special signals to regulate cell growth and 
division. In terms of cell division, cancer cells differ from normal cells in the following four 
ways
45
. 
First, external growth factors are required by normal cells to divide. When synthesis of 
these growth factors is inhibited by normal cell regulation, the cells stop dividing. While, 
cancer cells can proliferate without these positive growth factors, so they divide whether or 
not these factors are present. As a result, cancer cells have become independent cells, not 
behave as part of normal tissue anymore.  
Second, normal cells show contact inhibition; that is, they respond to contact with other 
cells by ceasing cell division. Since cancer cells have lost this characteristic, they will 
continue to grow even after they touch other cells, causing a large mass of cells to form. 
These cancer cells may even penetrate the normal cells cause metastasis.  
Third, the ability of normal cells to replicate DNA is about fifty times, and then they die, 
are replaced in a controlled and orderly manner by new cells. In adult cells, each time the 
chromosome replicates, the ends (telomeres) shorten, limiting the number of times the cell 
can divide. However, telomerase is activated in cancer cells, allowing an unlimited number 
of cell division.  
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Fourth, normal cells cease to divide and die when there is DNA damage or when cell 
division is abnormal. Cancer cells continue to divide, even when there is a large amount of 
damage to DNA or when the cells are abnormal. These progeny cancer cells continue to 
divide they accumulate even more damaged DNA.  
2.1.3 Genetics of Cancer 
A small number of genes in the human genome are associated with cancer. Alterations 
in these genes cause different forms of cancer. These malfunctioning genes can be broadly 
classified in to three groups, proto-oncogenes, tumor suppressors, and DNA repair 
genes
46,47,48
. Proto-oncogenes and tumor suppressor genes work as the accelerator and brakes 
of the cell growth, respectively. Proto-oncogenes accelerate controlled cell growth, while 
tumor suppressors slow cell growth. The overactivity mutation of proto-oncogenes and 
underactivity of tumor suppressor genes lead to cells proliferate abnormally and create cancer. 
The third group includes DNA repair genes, which help prevent mutations that induce 
cancer.  
Oncogenes are the mutated forms of proto-oncogenes that activate producing signaling 
molecules, resulting in an increased production of factors that stimulate cell growth. For 
example, MYC is a proto-oncogene that codes for a transcription factor. Mutations in MYC 
convert it into an oncogene associated with seventy percent of cancers. RAS is another 
oncogene that normally functions as an “on-off” switch in the signal cascade. Mutations in 
RAS cause the signaling pathway to remain “on”, leading to uncontrolled cell growth. About 
thirty percent of tumors- including lung, colon, thyroid, and pancreatic carcinomas- have a 
mutation in RAS
46
.  
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Figure 2.1 Illustration of proto-oncogene to oncogene
46
 
Tumor suppressor genes in normal cells serve as braking signals during phase G1 of the 
cell cycle
48
. When working properly, the proteins made by tumor suppressor genes control 
the processes of cell growth and cell death, which prevent tumor formation. If a tumor 
suppressor gene is mutated, the normal brake mechanism will be disabled, leading to tumor 
formation or growth (cangenom). 
 
Figure 2.2 Illustration of tumor suppressor genes
46
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During cell division, mistakes may occur. Errors in DNA replication can lead to 
mutations
49
. If these mutations occur in proto-oncogenes or tumor suppressor genes, DNA 
repair genes will correct the damage to chromosomes, thereby minimizing mutation in the 
normal cells. When these genes are mutated or altered, the mistakes that can not be repaired 
will accumulate and increase the frequency of cancerous changes in the cells. 
 
Figure 2.3 Errors in DNA replication
49
 
2.1.4 New Treatments for combating cancer 
The traditional treatments for combating cancer include surgery, radiation and 
chemotherapy
6,7
. Among them, surgery is the oldest form of cancer treatment, which is used 
to remove solid tumors. Even today, surgery is still the first treatment for early stage cancers 
and benign tumors. However, it is not a good option in many patients with malignant tumors 
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due to the tumor size, location and presence of metastases. Radiation is considered as a local 
therapy, which kills cancer cells in a specific localized area of the body with high-energy 
rays
7
. It damages DNA and stops DNA’s replication in the rapidly divided cancer cells. At 
the same time, radiation also kills some normal cells, but because normal cells are growing 
more slowly, they are able to repair the radiation damages if radiation treatments are given in 
a small daily dose. In contrast to local therapy, chemotherapy is systemic therapy, which 
travels throughout the body
6
. Most of the chemotherapy drugs are toxic compounds to 
interrupt the synthesis of precursors for DNA replication. While other drugs damage DNA 
extensively and stop the DNA’s replication. However, the side effects of both radiation and 
chemotherapy are severe, they kills a large amount of normal cells and cause low white blood 
cell count, gastrointestinal distress and hair loss.  
Hormone Therapy 
Hormones are important factors that affect normal cell growth. Even though cancer cells 
have lost part of the normal responses to growth factors, some types of cancer cells still 
require hormones to grow, such as breast cancer
50
 and prostate cancer
51
. Hormone therapy 
tries to starve the cancer cells of these hormones, make cancer cells grow more slowly or 
even kill cancer cells. This is usually done with drugs that stop the production of the 
hormones or interfere with the activity of the hormone. For example, estrogens are the 
primary female sex hormones, which are required by some breast cancer cells for growth. 
Blocking the binding site for estrogen is the effective way to slow the growth of these breast 
cancers. Tamoxifen and Raloxifene
52,53
 are the typical examples of this type of drugs. 
Similarly, some prostate cancer cells require androgen hormone to grow. Selective androgen 
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receptor modulators are drugs that block the binding of testosterone to these cancer cells, 
inhibiting their growth and possibly preventing prostate cancer.   
Antiangiogenesis therapy 
Angiogenesis, the formation of new blood vessels, is a physiological process controlled 
by chemical signals in the body. These signals can help repair the damaged blood vessels and 
form the new blood vessels. On the other hand, angiogenesis inhibitor interferes with the 
formation of new blood vessels. These two effects are balanced so that new blood vessels 
form only when and where they are needed
54
.  
Angiogenesis performs a key role in the growth of cancer. Normally small solid tumor 
(<1-2cm) are not vascularized. To spread, tumors can produce angiogenesis signaling 
molecules to cause the blood supply to form, or stimulate nearby normal cells to give off 
chemical angiogenesis signals. The new formation of blood vessels provide growing tumor 
with oxygen and nutrients, allowing the cancer cells to invade nearby normal tissues, and to 
move to other areas of the body.  
 
Figure 2.4 Process of angiogenesis formation
54
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In the early 1970s Dr. Judah Folkman
55
 first suggested inhibiting new blood vessel 
formation as a new approach to “starve” cancer cells. In the next few decades, several 
angiogenesis inhibitors were developed, which interfere with the angiogenic process to 
inhibit tumor progression and metastatic progression that accompanies with the growth of 
tumor. Until 2004, Bevacizumab
56
, the first commercially angiogenesis inhibitor, was 
approved by the U.S. food and drug administration (FDA) for certain metastatic cancers. It 
was shown to slow tumor growth, more important, to extend the lives of patients. After that, 
other drugs that inhibit angiogenic activity were approved by the FDA, including sorafenib 
(Nexavar®) for hepatocellular carcinoma and kidney cancer, sunitinib (Sutent®) and 
everolimus (Afinitor®) for both kidney cancer and neuroendocrine tumors, and pazopanib 
(Votrient®) for kidney cancer
56
.  
Chemoimmunotherapy 
Immunotherapy has been investigated for over a century as an attractive strategy for 
cancer treatment
57
. It is treatment that uses the patient's immune system to fight diseases such 
as cancer. This can be done either through immunization of the patient, in which case the 
patient’s own immune system is stimulated to work harder or smarter to attack cancer cells, 
or through administration of immune system components such as antibodies, in which case  
the patient's immune system is recruited to destroy tumor cells by the therapeutic antibodies.  
Chemoimmunotherapy strategically integrate immune-based therapy with chemotherapy. 
Chemotherapy drugs were attached to antibodies that are specific for some cancer cells. The 
cancer-cell-specific antibody then delivers the drug directly to cancer cells without harming 
normal cells, reducing the toxic side effects of chemotherapy
58
.  
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2.2 Current Advances in Nanoparticle Delivery Systems for Cancer Therapy 
2.2.1 Introduction 
Despite many advances in conventional cancer treatments, cancer therapy is still far 
from optimal because of the severe side effects. Thus, there is an urgent need to develop new 
and innovative technologies that could enhance the therapeutic efficacy and minimize the 
side effects. The past decade has witness tremendous advances in the field of nanoparticle 
delivery systems
10
,
12
. Several drug nanocarriers have been developed, including 
liposomes
14-15
, polymeric nanoparticles
15,59
 , and dendrimers
19,60
.  
As with any nanomaterial used in drug delivery, there are a number of important 
parameters for the successful development and manufacturing of targeted drug delivery 
vehicles
61
. These parameters include (a) the use of biodegradable and biocompatible 
materials which can be degraded or metabolized into non-toxic components and cleared 
quickly; (b) submicron size distribution and surface charge may affect the efficiency and 
pathway of cellular uptake by influencing the adhesion of the particles and their interactions 
with cells. (c) capability to increase drug stability and maximize drug action; (d) to increase 
the drug concentration at desired tumor sites and reduce damage on the normal tissues.  
Passive and active cancer targeting are the two strategies on delivering 
drug-encapsulated nanoparticles to tumor tissue
62,63
. Passive cancer targeting employs the 
unique properties of the tumor microenvironment, such as leaky tumor vasculature and a 
dysfunctional lymphatic drainage system. These features provide an enhanced permeability 
and retention (EPR) effect, which could accumulate nanoparticles in tumor tissues. As a 
result, the concentration of drug-encapsulated nanoparticles in tumors can be much higher 
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than those in normal tissue. Abraxane®, albumin-bound paclitaxel nanoparticles for the 
treatment of metastatic breast cancer, and Doxil®, a poly (ethylene glycol)-coated 
(PEGylated) liposomal system for doxorubicin (Dox) delivery, are representative examples 
of nanocarrier-based drugs using EPR effect for treatment of cancer
62
. However, this 
approach suffers from several limitations. For example, the EPR effect is not feasible in all 
tumors because the degree of tumor vascularization and porosity of tumor vessels can vary 
with the tumor type and status. The drug-encapsulated nanoparticles concentration is still 
insufficient at the tumor site
64
. In active targeting, active targeting ligands are attached to the 
surface of the nanoparticle for recognizing and binding to specific receptors overexpressed at 
the surface of cancer cells. Compare to passive targeting, active targeting can deliver 
drug-encapsulated nanoparticles to uniquely identified sites with minimal undesired harmful 
toxicity to non-cancerous cells adjacent to the targeted tissue. Currently the major problem in 
active targeting is ligand-drug conjugate and to enhance the systems by encapsulating the 
drug in nanoparticles efficiently. 
2.2.2 Liposome  
As early as 1970s, liposomes had been suggested as drug carriers in cancer 
chemotherapy by Gregoriadis et al
65
. Since then, the liposome systems as drug carrier are 
being extensively studied. Liposomes or lipid vesicles are composed of either synthetic or 
natural phospholipids
11
, which contribute to the predominant physical and chemical 
properties of a liposome, including permeability, charge density and steric hindrance. It 
appears that different applications require different types of liposomes. There are three major 
types of liposome based on the particle size, the small unilamellar vesicles (SUV< 0.1µm), 
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the multi-lamellar vesicles (MLV> 0.1 µm) and the large unilamellar vesicles (LUV >0.1 
µm). MLV and LUV are cleared rapidly from the circulation, while SUV remains in 
circulation system for longer period of time. As a proven candidate for delivery of a wide 
range of therapeutics, liposomes can encapsulate their payload by several methods, as shown 
in Figure 2.5.  
In the early days, the design of liposome drug delivery system is relatively simple. 
Water soluble drug and DNA is designated to be encapsulated in their internal aqueous 
compartment, whereas lipid soluble drug can be embedded within the phospholipids bilayer. 
Up to now, the strategies are becoming increasingly complex to fulﬁll the growing 
requirement for treating several different diseases. A significant advanced liposomal delivery 
is the surface chemical modification of liposomes with certain polymers, such as poly 
(ethylene glycol) or other polymers including poly(acrylamide) and poly(N-vinyl 
pyrrolidine)
66
. This strategy could impart the in vivo long-circulating time to the liposomes. 
The first approved liposomal formulations of anticancer drugs for human use, Doxil® has 
achieved the most prolonged circulation to date, with a terminal half-life of 55 hours in 
humans
67
.  
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Figure 2.5 Diagram of a bilaminar liposome. The hydrophobic region traps drugs in the central 
core when the liposomes are prepared. The outer surface can be functionalized with ligands for 
active targeting or PEGylated
14
.  
Another significant advance in development of liposome-based drug delivery is 
incorporation of targeting moieties. By attaching targeting ligands to the liposomes surface, 
liposomes can search for and attach themselves to the specific receptors on tumor cell 
surfaces
37
. For example, the folate attached to the outer surface of liposomes is able to 
conjugate with the folate receptors overexpressed on tumor cell surfaces, which can avoid 
nonspecific attacks on normal tissue and increase cellular uptake within target cancer cells.  
As one of the most successfully drug delivery systems that are currently in clinical use, 
liposomes-based nanoparticles offered us a wide range of tools for the construction of more 
complex and multifunctional devices in pharmaceutical application. 
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Figure 2.6 Active and passive targeting of cells for drug targeting using liposomes
68
. 
2.2.3 Polymeric Nanoparticles 
Polymeric nanoparticles have been investigated as another attractive delivery system for 
cancer treatment since liposome due to their favorable physiochemical properties, such as 
controlled size distribution, relatively high drug carring capacity, and tunable properties
69
. 
Recently, several polymer-mediated delivery systems, including polymer micelles, 
polymer-drug conjugates, polymer-drug polyplexes, and hydrogels, have been developed to 
improve efficacy of drug delivery
70
. These novel polymeric nanoparticles are expected to 
protect the drug from enzymatic digestion and rapid clearance, as well as providing the 
potential for controlled release. 
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Figure 2.7 Typical length scales of responsive nanoscale drug delivery systems
70
. 
Polymer Micelles 
Most polymer micelles are formed with hydrophobic interior and a hydrophilic corona 
by amphiphilic block copolymers. Hydrophobic or water-insoluble drugs can be encapsulated 
in the hydrophobic core like surfactant micelles. Comparing with classic surfactant micelles, 
the thermodynamic and kinetic stability of polymer micelles is better, which allow them to 
retain integrity, even after extreme dilution (e.g. intravenous injection) or extended 
circulation time
40
. Polymeric micelles also have several advantages over other nanosized 
drug delivery systems. One favorable property of polymer micelles is their moderate size 
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distribution. The typical micelle size (20-100 nm) is small enough to avoid or minimize rapid 
uptake by RES while large enough to avoid renal clearance, which allows prolonging the 
circulation time of these particles in human body
10
. Another favorable property is that 
physical encapsulation of hydrophobic drugs within polymer micelles won’t affect their 
bioavaibility or deactivate the drug’s active site71. 
 
Figure 2.8 Schematic drawing of polymeric micelle (a). Micelle conjugated with a targeting 
ligand (b). Micelle containing an incorporated contrast agent or chelated imaging moieties (c). 
Micelle modified for triggered drug release (d). Either the hydrophilic or hydrophobic polymer 
can be rendered thermo/pH/light/ultrasound-sensitive. Optimized micelle for anticancer 
therapy, bearing targeting ligands, contrast agents or imaging moieties, therapeutic drugs and 
polymers suitable for triggered, controlled release (e)
40
. 
By modifying the structure of single copolymer monomer, different polymer micellar 
formulations for anticancer therapy can be achieved, as shown in Figure 2.8
40
. Targeting 
ligands can be attached to the outer surface of micelles which recognize and bind to specific 
receptors overexpressed in tumor cells. Incorporation or chelation of imaging moieties 
provides an efficient method for tracking micelles in vivo for biodistribution studies. 
Moreover, pH-, thermo-, light-, or ultrasound-sensitive block copolymers allow for 
controlled micelle dissociation and triggered drug release
16
. 
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Table 2.1 Polymeric Micelles in Clinical Trials 
 
Currently, five micellar formulations for cancer therapy have been tested in clinical 
trials , as shown in Table 2.1, including NK012
72
, NK105
73
, SP1049C
74
, NC-6004
75
, and 
Genexol-PM
76
. Among these five formulations, Genexol-PM has been granted 
FDA-approval to be used in patients with breast cancer.  
Polymer-Drug Conjugates 
Synthetic polymer-drug conjugate used for drug delivery was first proposed by 
Ringsdorf in the mid-1970
77
. In this model, both chemotherapeutic agents and homing 
moieties are attached to the same polymeric carrier covalently, so that more drug molecules 
to the tumor site and active targeting could be achieved at the same time. Unlike polymeric 
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micelles, they do not entrap the drug inside. Since then, polymer-drug conjugates has become 
one of the fastest growing fields and generated enormous attention
78
. Various architectures of 
polymers have been developed as drug carriers due to their several advantages, including (1) 
an enhancement of drug bioavailability in aqueous solution; (2) protection of drug during 
circulation; (3) a reduction in immunological body response; (4) the ability to provide active 
or passive targeting of the drug to the site of tumor; (5) the possibility to include several 
other active components to form an advanced complex drug delivery system
17
.  
 
Figure 2.9 Model for targetable polymer-drug conjugates according to Ringsdof
77
.  
In the past decades, nearly a dozen polymeric conjugates moved into the clinical trial 
stage
79
. Clinical results collected among these polymer-drug conjugates, poly (L-glutamic 
acid) (PG)-paclitaxel (PG-TXL) has advanced to Phase III clinic trials, which is positioned as 
the first-line therapy for metastatic breast cancer and advanced ovatian cancer. Despite 
progress, further generation of polymer-drug conjugates remain a number of challenges, such 
as the possibility to modulate rates of degradation, accurate control of polymer weights and 
molecular weight distributions, and to facilitate noninvasive monitoring of drug delivery 
efficiency, et al.  
Table 2.2 Polymer-drug conjugates in clinical trials
79
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Conjugates Indication Status Company 
HPMA-doxorubicin (PK1; 
FCE28068) 
Lung and breast 
cancers 
Phase II as of 
2002 
Pfizer; Cancer 
Research 
Campaign UK 
HPMA-doxorubicin-galactosamine 
(PK2, FCE28069) 
Hepatocellular 
carcinoma 
Phase I/II Pfizer; Cancer 
Research 
Campaign UK 
HPMA-camptothecin (PNU166148) Solid tumors Phase I; 
discontinued 
Pfizer; Cancer 
Research 
Campaign UK 
HPMA-paclitaxel (PNU166945) Solid tumors Phase I; 
discontinued 
Pfizer; Cancer 
Research 
Campaign UK 
HPMA-platinate (AP5346, 
ProLindac) 
Ovarian, melanoma, 
and colorectal 
cancers 
Phase I Access 
Pharmaceutical 
PEG-Camptothecin (Pegamotecan) Solid tumors Phase I; 
discontinued 
Enzon 
PEG-SN38 (EZN-2208) Solid tumors Phase I; 
initiated as of 
October 2007 
Enzon 
Polymeric micelles (NK911) Pancreatic cancer Phase II Nippon Kayaku, 
Japan 
Cyclodextrin-based polymer-CPT 
(IT-101) 
Solid tumors Phase I Insert Therapeutics 
Carboxymethyldextran-exatecan 
(DE-310) 
Solid tumors Phase I Daiichi 
Pharmaceuticals, 
Japan 
PG-TXL (CT-2103, Xyotax) Lung, ovarian, 
colorectal, breast, 
and esophageal 
cancers 
Phase III Cell Therapeutics 
PG-camptothecin (CT2106) Colorectal, lung, 
and ovarian cancers 
Phase I Cell Therapeutics 
 
Polymer-Drug Polyplex 
Polymer-drug polyplexes are formed by chain entanglements and hydrophobic 
interactions between polymers and nucleic acids, low molecular weight drugs, or proteins. 
  25 
These structures are expected to have increased mechanical stability than polymeric 
micelles
80
.  
2.2.4 Dendrimers  
Dendrimers represent a novel class of polymeric material that possesses a number of 
unique physical-chemical properties, including a highly regular branching pattern, a low 
polydispersity index, and a well-defined number of peripheral groups
11
. Since Tomalia et al 
and Newkome et al first reported their dendrimer synthesis work in the early 1980s; several 
novel dendritic scaffolds have been synthesized over the past two decades
81,19, 82
. At the very 
beginning, studies on dendrimers focused on their syntheses and physical- chemical 
properties, and its potential application in biological applications was exploited only in the 
past few years. By comparing the features of dendrimers with those of conventional polymers, 
dendritic architectures provide several advantages for drug delivery applications
83
. For 
example, unlike polymeric micelles, dendrimers do not dissociate upon dilution because they 
are covalent bound, which could provide an efficient way to overcome the problem of sudden 
release of drug during circulation. In addition, more drug molecules and targeting groups can 
be attached to the well-defined peripheral groups of dendrimers to increase therapeutic 
efficacy. Furthermore, the globular shape of dendrimers could affect their biological 
properties, leading to reproducible pharmacokinetic behavior as opposed to the random coil 
structure of linear polymers.  
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Figure 2.10 Examples of several dendritic scaffolds extensively studied for potential drug 
delivery applications: (a) PAMAM, (b) poly(glycerol-succinic acid) dendrimer, (c) Boltorn® 
and, (d) hyperbranched polyglycerol. 
Noncovalent encapsulation of drugs 
Inspired by the encapsulation mechanisms of liposome and polymeric micelles for drug 
delivery, initial studies of dendrimers as drug delivery carriers focused on their use as 
unimolecular micelles or ‘ordendritic boxes’ to encapsulate drug molecules by noncovalently 
bonding
84
. For example, hydrophobic drugs and dye molecules were trapped into various 
dendrimer hydrophobic cores, and DNA was complexed with dendrimers for gene delivery 
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applications. As mentioned above, an advantage of using dendrimers rather than polymeric 
micelles is that the micellar structures of dendrimer are maintained at all concentrations. 
However, this method suffers from shortcomings that it is difficult to breakdown the 
dendritic scaffolds and to control the release of molecules from the dendrimer core.  
A promising novel approach to controlling the release of drugs from the dendrimer 
includes introduction of pH-sensitive hydrophobic acetal groups on the dendrimer periphery. 
The Haag group developed a library of intelligent core/shell dendrimer structures based on 
hyperbranched polyglycerol (PG)
85
. The dendritic nanocarriers were assembled by attaching 
a PEG shell to the hyperbranched PG core through a pH-labile imine bond which was 
designed to cleave off at pH 5.0. This dendrimer can be used to encapsulate the anticancer 
drug doxorubicin and a NIR imaging dye indotricarbocyanine. 
 
Figure 2.11 Unimolecular dendritic nanocarriers for supramolecular encapsulation of 
biologically active compounds. Controlled release after triggered shell cleavage (e.g. 
pHcontrolled)
85
. 
Covalent dendrimer-drug conjugates 
Following Ringsdorf’s idea of polymer-drug conjugates, active species and the targeting 
moiety can be covalent linked to the peripheral end-groups of a dendrimer to create a 
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multi-functional drug delivery platform. The drug loading can be tuned by altering the 
dendrimer’s generation number, and release of the drug can be controlled by the chemical 
degradable linkage between the drug and dendrimer
86
. In most cases, the drugs are linked to 
the periphery groups of dendritic scaffold through an easter or amide bonds. In addition to 
these two linkage types, hydrazone, carbamate, disulfide, and imine types have also been 
used. Each of the linkages has their own inherent and differential cleavage mechanisms that 
separate the drug molecule from the carrier. For instances, easter, carbamates and hydrazone 
collapse depend on environmental pH, while amides and peptidic sequences need enzymatic 
hydrolysis for their degradation and release of the drug molecule.  
 
Figure 2.12 Design of a dendritic conjugate by attaching multiple copies of drugs and 
solubulizing groups to the scaffold. Environment-responsive linker system can facilitate 
triggered-drug release
86
. 
Duncan et al. have prepared conjugates of polyamidoamine (PAMAM) dendrimer with 
cisplatin, an insoluble anticancer drug with nonspecific toxicity
81
. The PAMAM-platinate 
conjugate showed increased solubility, decreased systemic toxicity (3- to 15- fold) than 
cisplatin and selective accumulation in solid tumors. In addition, Duncan collaborated with 
Veronese et al. and first synthesized a novel monodisperse PEG-dendrons
60
. This branched 
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PEG-based architecture was found to be non-toxic to an endothelial-like cell line at 
concentrations of 4 mg/mL for over 72h.  
Haag group has dedicated their effort on developing novel dendrimer-drug conjucates in 
the recent years
18
. They synthesized thiolated polyglycerol by coupling PEG-maleimide and 
DOXO-EMCH onto the scaffold in a one-pot method, thereby yielding 
polyglycerol-doxorubicin conjugate with a PEG-shell. In vitro stability studies indicated that 
this pH-triggered conjugate could release less than 5% free doxorubicin at pH 7.4, while have 
a half-life of 3.5 h at pH 4.0. The conjugate also showed excellent antitumor efficacy in the 
ovarian carcinoma A2780 xenograft model.  
Although dendrimer-drug conjugates exhibited substantially positive biological results 
in current studies, most of the conjugates suffer from a general and serious setback
87
. It is 
hard to generate homogeneous distribution of ligand-bound dendritic carriers because the 
number and type of ligand species and synthetic steps varies. Such an inhomogeneous ligand 
distribution on dendritic surface will hinder their implication for eventual biological and 
clinical trials.  
2.3 Self-Assembling Ionic-Complementary Peptides 
2.3.1 Introduction 
Molecular self-assembly is a spontaneous and reversible process by which molecules 
and individual entities into organized structures at multiple length scales. Recently, 
nanotechnology through molecular self-assembly become tremendously important in various 
research areas, especially as a fabrication tool. Up to now, it is still the only practical 
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approach for producing a variety of nanostructures, and conveys a kind of strong power to 
break conventional top-down fabrication techniques. This ubiquitous but unique free-energy 
driven process strikes a new episode to create artificial nanoscale scaffold.  
In the bio-world, amino acids and short peptides have been considered to be useful 
building blocks for materials engineering owing to their assortment of functional groups. 
Over the past decades, extensive research activities have been devoted to the design and 
fabrication of novel biomimetic nanobiomaterials through peptide self-assembly 
23
. Many 
classes of synthetic peptides have been discovered and explored in various biomedical 
applications, ranging from drug delivery
88
, tissue engineering
89
, 3D cell culture
90
 to SiRNA 
and gene delivery. Self-assembling peptides are able to form stable and regularly patterned 
macroscopic structured aggregates through non-covalent interactions, including ionic bonds, 
hydrogen bonds, hydrophobic and van der Waals interactions
24
. Even though each of the 
forces is not strong, the collective interactions can lead to very stable structures and 
materials.  
As early as 1993, Zhang and colleagues has pioneered the studies on a new class of 
peptide EAK16 originally derived from a left-handed Z-DNA binding protein in yeast
91
. This 
class of peptides has a specific structure of alternating hydrophilic and hydrophobic amino 
acid residues, which tend to form β-sheet rich fibers. Such a regular assortment and 
arrangement of functional residues ensure the peptide monomers assembly into various 
ordered structures, such as filaments, layers, and nanotubes. They are stable across a broad 
range of temperature, wide pH ranges in high concentration of denaturing agent urea and 
guanidium hydrochloride
22
. Besides, they also possessed relatively good biocompatibility 
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and biodegradability
92
. These nanostructures could act as a basis for fabricating more 
functional materials with diverse properties, which is believed to have considerable potential 
for a number of applications in tissue engineering, drug delivery system and scaffold 
engineering. Since then, many self-assembly ionic complementary peptides have been 
systematically studied, as listed Table 2.3
93
. These peptides are either derived from the 
segments of existing proteins or rationally designed to mimic and understand protein 
secondary structures. As an emerging potential delivery material in biotechnology, a good 
understanding of the self-assembling process will help us design smarter peptide 
nanostructures for specific goals. The following sections aim to outline the detailed 
information of self-assembly ionic complementary peptides, focusing on the factors 
influencing their nanostructure formation. 
Table 2.3 the family of self-assembling ionic-complementary peptide
93
 
Name Charge distribution sequence Type Structure 
RADA16-I +−+−+−+−: n-RADARADARADARADA-c I β 
RGDA16-I +−+−+−+−: n-RADARGDARADARGDA-c I r.c. 
RADA8-I +−+−: n-RADARADA-c I r.c. 
RAD16-II ++−−++−−: n-RARADADARARADADA-c II β 
RAD8-II ++−−: n-RARADADA-c II r.c. 
EAKA16-I +−+−+−+−: n-AEAKAEAKAEAKAEAK-c I β 
EAKA8-I −+−+: n-AEAKAEAK-c I r.c. 
RAEA16-I +−+−+−+−: n-RAEARAEARAEARAEA-c I β 
RAEA8-I +−+−: n-RAEARAEA-c I r.c. 
KADA16-I +−+−+−+−: n-KADAKADAKADAKADA-c I β 
KADA8-I +−+−: n-KADAKADA-c I r.c. 
EAH16-II −−++−−++: n-AEAEAHAHAEAEAHAH-c II β 
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EAH8-II −−++: n-AEAEAHAH-c II r.c. 
EFK16-II −−++−−++: n-FEFEFKFKFEFEFKFK-c II β 
EFK12-I −+−+−+: n-FEFKFEFKFEFK-c I β 
EFK8-I −+−+: n-FEFKFEFK-c I β 
KFE8-I
T
 +−+−: n-KFEFKFEF-c I β 
KFE8-I +−+−: n-FKFEFKFE-c I β 
KFE12-I +−+−: n-FKFEFKFEFKFE-c I β 
KFE16-I +−+−+−+−: n-FKFEFKFEFKFEFKFE-c I β 
KIE12-I +−+−+−: n-IKIEIKIEIKIE-c I β 
KVE12-I +−+−+−: n-VKVEVKVEVKVE-c I β 
KFQ12 +−+−+−: n-FKFQFKFQFKFQ-c I β 
ELK16-II −−++−−++: n-LELELKLKLELELKLK-c II β 
ELK8-II −−++: n-LELELKLK-c II β 
EAK16-II −−++−−++: n-AEAEAKAKAEAEAKAK-c II β 
EAK12-a ++−−++: n-AKAKAEAEAKAK-c II r.c. 
EAK12-b +−−++: n-AKASAEAEAKAK-c N/A r.c. 
EAK12-c +−−−++: n-AKAEAEAEAKAK-c N/A r.c. 
EAK12-d −−−−++: n-AEAEAEAEAKAK-c IV/II α/β 
EAK8-II −−++: n-AEAEAKAK-c II r.c. 
P18-a −−−−++++: n-GELELELEQQKLKLKLKG-c IV α/β 
P18-b −+−++−+−: n-GELKLELKQQKLELKLEG-c N/A α/β 
P18-c −−++−−++: n-GELELKLKQQELELKLKG-c II α/β 
P18-d −−−−++++: n-GELEAELEQQKLKAKLKG-c IV α/r.c. 
P17-a −+−+−+: n-ETATKAELLAKYEATHK-c I α/β 
P17-bc −+−+−+: n-ETATKAELLAKZEATHK-c I α/β 
P11-I +−: n-QQRQQQQQEQQ-c I α/β 
P11-II +−: n-QQRFQWQFEQQ-c I α/β 
LEK16 −−++−−++: n-YLEELLKKLEELLKKL-c II α 
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LEK9 +−+−: n-YKLELKLEL-c I β 
IDR16 −−++−−++: n-YIDDIIRRIDDIIRRI-c II α 
IDR9 +−+−: n-YRIDIRIDI-c I β 
P6-c n-KTVIIT-c N/A r.c. 
P6-d n-STVIIT-c N/A β 
P6-e +−: n-KTVLIE-c I β/r.c. 
P6-f +−: n-KTVIVE-c I β/r.c. 
β: β-sheet; α: α-helix; r.c.: random coil; N/A: not applicable. 
2.3.2 Molecular Structure  
Among many self-assembling peptides, the class of ionic complementary peptides is of 
special interest, because they possess several uncommon important features due to their 
specific assortment and arrangement of amino acid residues
93,91
. First, one critical important 
factor is their varieties of charge distribution. The ionic complementary sides have been 
classified into several modules by their alternating arrangement of negatively and positively 
charged residues along the peptide backbone. The most widely studied modules of charge 
distribution are modulus I (− + or + −), modulus II (− − + + or + + − −) and modulus IV (− − 
− − + + + + or + + + + − − − −). These ordered charge distribution generate unique 
electrostatic interactions, which promote stable molecular self-assembly besides usual 
hydrogen bonding and hydrophobic interaction. In addition, the charge orientation can also 
be tuned in the reverse direction, which can yield entirely different peptides.  
A second critical feature is that the new ionic-complementary peptides can be derived 
by using different amino acids to replace those of the existing peptides with the same charge 
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distribution
94
. For example, RAD16 can be obtained from EAK16 by replacing the residues 
glutamic acid (E) and lysine (K), with arginine (R) and aspartic acid (D), respectively. 
Similarly, the replacement of the hydrophobic residue alanine (A) of EAK16 with 
phenylalanine (F) or leucine (L) will generate two other ionic-complementary peptides, 
EFK16 and ELK16, respectively. Their intrinsic properties, secondary structures and 
biological activities can be changed with the replacement of new amino acids.  
A third feature is the specific peptide chain lengths required to exhibit ionic 
complementarity. The length of self-assembling ionic-complementary peptides depends on 
the alternating hydrophobic and hydrophilic residues in the peptide sequence (Table 2.1). The 
minimum number of amino acids required to build modulus I peptides is four, while the 
creation of modulus II and modulus IV peptides require eight and sixteen amino acids, 
respectively. Polypeptides such as poly-EAK can be designed by increasing the number of 
sequence of the short peptides to the desired length.  
2.3.3 Peptide Self-Assembly Mechanism and Controlling Factors 
A good understanding and precise control of peptide self-assembly is critical to tune the 
formation of peptide nanostructure, develop peptide-drug complexes, and further control the 
structure and size of the complex
93
. There are many internal and external factors that can 
influence peptide self-assembly formation, including (a) amino acid sequence, (b) molecular 
size, (c) peptide concentration, (d) charge distribution, (e) solution pH, (f) solvent, (g) 
temperature, (h) surface and its property and (i) mechanical force. The effects of amino acid 
sequence, charge distribution peptide concentration, and solution pH on peptide 
nanostructure formation, which are most relevant to this thesis work, are discussed below. 
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Effect of Amino Acid Sequence 
The information for peptide self-assembly is encoded in the amino acid sequence. The 
type, number and arrangement of amino acids in the sequence are critical to form and tune 
the secondary structures and self-assembled nanostructures of the peptides. By altering the 
amino acid sequence, the structural and functional properties of the peptide can be modulated. 
One classic example is RAD16-II (Ac-RARADADARARADADA-CONH2), which is 
modified from EAK16-II by replacing R with E and D with K. RAD16-II is similar to 
EAK16-II, which is highly soluble in water and forms a stable β-sheet structure. Moreover, 
the β-sheets can self-assemble into even higher macromolecular structures to form hydrogels 
with greater than 99% water content through self-complementary ionic interactions, 
hydrophobic interactions and backbone hydrogen bonding between the alanine methyl 
groups
95
. 
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Figure 2.13 Self-assembling peptide RAD16-I nanofiber scaffold hydrogel. Left) Amino acid 
sequence of RAD16-I and molecular model of a single RAD16-I nanofiber (dimensions are ≈6 
nm long, 1.3 nm wide, and 0.8 nm thick); tens and hundred thousands of individual peptides 
self-assemble into a nanofiber. Right) SEM image of RAD16-I nanofiber scaffold. Scale bar is 
0.5 μm or 500 nm
95
.  
Effect of Charge Distribution 
In addition to the type of amino acid, the charge distribution of the peptide sequence has 
significant impact on its nanostructure formation
22
. For example, Hong has studied the 
nanostructure formation of self-assembly peptide EAK16s, including EAK16-I, EAK16-II 
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and EAK16-IV. They have the same amino acid composition (A, E and K), while different 
sequence and charge distribution. The amino acid sequences of these peptides are 
AEAKAEAKAEAKAEAK for EAK16-I, AEAEAKAKAEAEAKAK for EAK16-II, and 
AEAEAEAEAKAKAKAK for EAK16-I, respectively. The first two self-assembly peptides, 
EAK16-I and EAK16-II form fibrillar assemblies, while EAK16-IV forms globular 
aggregates at pH 7. Further studies have suggested that both of EAK16-II and EAK16-IV 
contain β-sheets in their substructures. The β-sheets from EAK16-II further elongate and 
stack to form linear fibrils, while the assembly of EAK16-IV may bend or fold to form 
globular aggregates due to the stronger intramolecular electrostatic attractions between the 
amino acid groups of lysine and the carboxylic acid groups of glutamic acid. The 
experimental results are supported by Monte Carlo simulations. Therefore, the charge 
distribution has an effect on secondary structure of peptides and further self-assembly. 
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Figure 2.14 (A) Three-dimensional molecular model of EAK16s. The top, middle and bottom 
schemes represent the EAK16-I, EAK16-II and EAK16-IV structures, respectively. (B) A 
scheme of EAK16-II self-assembly through hydrophobic interaction and ionic-complementarity. 
In addition to the hydrogen bonding, hydrophobic and electrostatic interactions help to make 
stable β-sheets. A proposed model of EAK16-II self-assembly into β -sheet-based aggregates. 
We proposed that the peptides self-assemble in a fashion of antiparallel to favor the minimum 
energy state. In fact, some evidence has shown that EAK16-I and -II have a high frequency 
peak from Fourier-transform infrared (FT-IR) measurements, which implies the antiparallel 
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β-sheet formation. (C)AFM images of peptide self-assembled nanostructures from (a) EAK16-I, 
(b) EAK16-II and (c) EAK16-IV
22
. 
Effect of peptide concentration 
Peptide concentration is another critical factor affecting peptide self-assembly and 
controlling the formation of nanostructure. In colloidal and surface chemistry, surfactant can 
form micelles above the concentration called the critical micelle concentration (CMC). 
Similar to surfactants, self-assembly peptide is expected to have a critical aggregation 
concentration (CAC) that governs the assembly process because of its amphiphilic structure. 
This CAC has been reported for many amphiphilic peptides and proteins.  
Because of the strong molecular interactions among the peptides, it is acceptable that the 
CAC values of self-assembling ionic-complementary peptides are much smaller than the 
CMC of most surfactants (around 10
-3
 to 10
-2
M). Fung et al reported that EAK16-II have a 
CAC of ~0.1 mg/ml (60 μM) by surface tension measurements96. AFM studies of EAK16-II 
reveal that fiber networks are observed when the peptide concentration is above the CAC, 
while isolated filaments and globules are formed at concentrations below the CAC. In 
addition, the peptide concentration is related to fibril size and network density as well. AFM 
studies also showed that EAK16-I assembly undergo two nanostructure transitions. The first 
transition from globules to fibril assemblies occurs at the peptide concentration of 0.05 
mg/mL (30 μM); the second transition involves dramatic increase in the fibril size as the 
concentration rises above 0.3 mg/ml (180 μM). 
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Effect of solution pH 
Biological systems are extremely sensitive to pH, which indicates that the solution pH is 
an important external factor that influences peptide and protein structures
22
. A pH change 
will have an effect on the ionic state of the charged residues and the net charge of peptides. 
This will further affect the self-assembly behavior of the peptide and protein 
folding/aggregation. An attractive class of PA molecules was found to be capable of 
changing morphology reversibly under the pH range of 6.6-7.4
97
. It consists of three main 
segments: a charged amino acid sequence, a β-sheet-forming peptide sequence, and a 
hydrophobic alkyl tail. The peptides would exist as either single molecules or spherical 
micelles at pH 7.4, and self-assemble into nanofibers upon the acidic environment (pH 6.6). 
Because the extracellular microenvironment of tumor tissue is slightly acidic (pH 6.6-7.4), 
this morphological change is ideal for in vivo cancer imaging and drug delivery applications. 
 
Figure 2.15 Schematic of the target reversible, pH-triggered morpho-logical transition of 
self-assembling peptide amphiphiles
97
. 
2.4 Self-Assembling Peptide-Mediated Hydrophobic Drug Delivery 
Self-assembling ionic complementary peptides EAK16-II has been extensively studied 
in our group as a novel and promising biomaterial for constructing drug delivery 
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carriers
21,98,99
. This unique amphiphilic peptide was utilized first to encapsulate hydrophobic 
microcrystals of ellipticine or neutral ellipticine through strong hydrophobic interaction. 
EAK16-II can form  -sheet rich nanofiber networks, which provide a protective 
microenvironment to stabilize not only microcrystal ellipticine, but also protonated ellipticine 
by increasing the peptid-to-ellipticine ratio (>5:1 by mass). Further studies showed that 
protonated EPT had a faster transfer rate than that of crystalline EPT from the peptide-EPT 
complex to EPC vesicles. In vivo studies also indicated that the complexes with protonated 
ellipticine were more effective at killing cancer cells. However, the stability of 
EAK16-II-EPT complexes was not very good upon dilution. The cellular toxicity (>60% cell 
viability) decreased quickly after 16 times dilution of the complexes. If we alter the charge 
distribution on the peptide sequence (EAK16-II: --++--++ vs. EAK16-IV: ----++++), no 
obvious difference have been observed both on the complex formation and molecular state of 
EPT in the complex
98
. On the other hand, EFK16-II, a more hydrophobic residue F replacing 
A in EAK16-II, stabilized neutral EPT molecules and microcrystalline EPT instead of 
protonated EPT due to a possible stronger hydrophobic interaction between peptide and EPT. 
In vitro studies showed that EFK16-II-EPT complexes possessed lower cellular toxicity 
against cancer cells than EAK16-EPT complexes, but it exhibited good stability upon 
dilution in water. 
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2.5 The Anticancer Agent Ellipticine 
Natural products have made an enormous contribution to cancer chemotherapy during 
the past 200 years. Small organic molecules (<3,000 Daltons) derived naturally from plants 
and microbes have provided a large number of useful anticancer drugs.  
Ellipticine (5, 11-dimethyl-6H-pyrido[4, 3-b] carbazole, Figure 2.16), a pyridocarbazole 
alkaloid first isolated in 1959 from Apocyanaceae plants
31
, has long been known for its 
significant anticancer and anti-HIV activities. The mechanisms of action of Ellipticine and its 
derivatives arresting cancer cell cycle progression have been extensively studied in the past 
few years
100
. It happened due to the following actions (1) DNA intercalation, (2) inhibition of 
topoisomerase Ⅱ, (3) covalent alkylation of macromolecules, and (4) induction of 
endoplasmic reticulum stress. However, the medical applications of ellipticine were hindered 
by a few problems. First, its aromatic, planar structure makes ellipticine an extremely 
hydrophobic agent, with a water solubility of 6.2x10
-7
 M. Such low water solubility limits its 
clinical application in aqueous solution. Second, severe side effects have been reported in 
clinical trials, including xerostomia, intravascular hemolysis, and bradycardia
33
. Therefore 
the novel delivery system is required to minimize the side effects and enhance the therapeutic 
efficacy.  
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Figure 2.16 (a) Chemical structure of ellipticine; (b) Planar structure of ellipticine. H: white, N: 
blue, C: canyon. 
Fung et al. have investigated the relationship between photophysical properties of 
ellipticine and the microenvironment of its nanocarrier
101
. It was found that ellipticine has 
three different molecular states: neutral, crystalline and protonated, with corresponding 
emission fluorescence peaks at 390-440 nm, 468 nm and 520 nm, respectively. Ellipticine 
exhibits a large Stokes shift (10000 cm
-1
) in polar solvent compared to that (8900 cm
-1
) in 
non-polar solvents. This dramatic spectra shift is attributed to the different structures adopted 
by ellipticine in different solvents. Therefore, the change in absorption and emission spectra 
will make it easy to be monitored either in physicochemical characterization or in vitro 
experiments.  
Among these molecular states of EPT, protonated EPT draw our attention because its 
good anticancer activity
21,39
. In vitro studies indicated that protonated EPT had much higher 
toxicity than crystalline EPT against both breast and lung cancer cells. Studies in living cells 
also revealed that only protonated EPT can exist in the nucleus. Although EPT delivery 
carrier has been extensively studied; the specific delivery carrier can encapsulate prescribe 
protonated EPT molecules still has not been reported. Therefore, it is necessary to develop 
new drug carriers that could deliver a drug with a prescribed molecular state and keep good 
stability upon dilution to maximize drug therapeutic effects. 
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Chapter 3 
Experimental Methods 
3.1 Materials  
Synthetic peptides EAR8-II, EAR8-a, ELR8-a, EAR16-II were obtained from 
CanPeptide Inc. (Montreal, Canada), stored at 4℃, and used without further purification. The 
sequences of peptides are AcN-AEAEARAR-CNH2 (Mw=913.98g/mol), 
AcN-AAEEAARR-CNH2 (Mw=913.98g/mol), AcN-LLEELLRR-CNH2 
(Mw=1082.30g/mol), and AcN-AEAEARARAEAEARAR-CNH2 (Mw=1782.92g/mol), 
respectively. A corresponds to alanine (ala), E to glutamic acid (glu), K to lysine (lys), and L 
to leucine (leu). The N-terminus and C-terminus of the peptide were protected by acetyl and 
amino groups, respectively. At pH~7, A and L is neutral, while E and R are negatively and 
positively charged, respectively. Figure 3.1 depicts the molecular structure of four peptides. 
The anticancer agent ellipticine (99.8% pure) was from Sigma-Aldrich (Oakville, ON, 
Canada) and used as received. Tetrahydrofuran (THF, reagent grade 99%) and dimethyl 
sulfoxide (DMSO, spectral grade 99%) were purchased from Calendon Laboratories Ltd. 
(Georgetown, ON, Canada) and Sigma-Aldrich (Oakville, ON, Canada), respectively. Cell 
culture reagents including F-12 Kaighn’s modification, minimum essential medium eagle 
(MEM), fetal bovine serum (FBS) and Trypsin-ETDA were purchased from Invitrogen 
Canada Inc. (Burlington, ON, Canada). Insulin and Phosphate buffer saline (PBS) was 
obtained from MP Biomedicals Inc. (Solon, OH, USA). MTT assay and CCK8 kit for cell 
viability tests were obtained from Sigma-Aldrich (Oakville, ON, Canada) and Dojindo 
Molecular Technologies, Inc., respectively. 
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EAR8Ⅱ: n-AEAEARAR-c 
 
EAR8-a: n-AAEEAARR-c 
 
ELR8-a: n-LLEELLRR-c 
 
EAR16Ⅱ: n-AEAEARARAEAEARAR-c 
Figure 3.1 Molecular structure of EAR8Ⅱ, EAR-a, ELR-a, and EAR16Ⅱ. 
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3.2 Peptide Solution and Peptide-Ellipticine Complex Preparation 
All arginine-rich ionic complimentary peptide solutions (0.05-0.5mg/mL) were prepared 
in pure water (18.2 M, Milli-Q A10 synthesis) to study their self-assembly behaviors. For the 
preparation of peptide solutions, certain amounts of lyophilized peptide powder were first 
dissolved in pure water, followed by sonication for 10 min to dissolve the peptide completely. 
Their self-assembly properties were studied by Axisymmetric Drop Shape Analysis-Profile 
(ADSA-P) technique and 1-anilino-8-naphthalene sulfonate (ANS) fluorescence assay. 
Secondary structure, size distribution and surface charge of peptides were characterized by 
Circular Dichroism (CD), Dynamic Light Scattering (DLS) and Zeta potential, respectively. 
The morphology and dimensions of peptide assemblies were examined by Atomic Force 
Microscopy (AFM) and Transmission Electron Microscopy (TEM).  
An appropriate amount of EPT crystals were first dissolved in THF at 0.4 mg/mL; 
aliquots of EPT-THF solution were then transferred to vials, and dried under gentle air 
blowing (through a 0.22μm filter) for ~10 min. Fresh peptide solution was then added to the 
vial, followed by mechanical stirring at 800 rpm for 24 h (as shown in Figure 3.2). An EPT 
control was prepared in pure water instead of peptide solution at the same EPT concentration, 
following the same procedure. The physiochemical properties of complexes were determined 
with same characterization techniques mentioned above. The complexes made of 0.1 mg/mL 
EPT and 0.5 mg/mL peptide were serially diluted to the lowest concentration of 4000× in 
pure water to study the colloidal stability and cytotoxicity of peptide-EPT complex upon 
dilution.  
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Figure 3.2 The schematic of preparation method of peptide-ellipticine complex   
3.3 Surface Tension Measurement  
The surface tensions of the peptides at an air-water interface over a period of 2.5 h were 
done by the Axisymmetric Drop Shape Analysis-Profile (ADSA-P) technique. The 
experimental setup and operation of ADSA-P were reported in an earlier publication and 
shown in Figure 3.3
102
. A pendant drop of the peptide solution was extruded at the tip of a 
vertical Teflon® capillary, which was connected to a motor-driven microsyringe, producing 
an axisymmetric drop boundary. This was done in a temperature-controlled environmental 
chamber saturated with water vapor. The entire system was isolated on a vibration-free table. 
The image of the pendant drop was acquired using an optical microscope and a CCD camera 
and digitally recorded for 1 h after the pendant drop was formed. Software was used to 
digitize the image and generate a profile of the pendant drop. A theoretical curve, governed 
by the Laplace equation of capillarity, was then fitted to the profile, generating the surface 
tension value as a fitting parameter. The typical standard deviations of all measurements 
were less than 0.2 mJ/m2. 
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Figure 3.3 Schematic of ADSA-P experimental setup 1-Work Station 2-Light Source 3-Diffuser 
4-Syringe 5-Environment Chamber 6-Stage 7-Microscope 8-Lens 9-Camera 10-Monitor 
11-Stage 12-Computer 
3.4 Fluorescence Spectroscopy 
A Photon Technology International Spectrafluorometer (Type QM4-SE, London, 
Canada) with a continuous xenon lamp as the light source was employed to study the EPT 
fluorescence in the complex. The excitation and emission slit widths were set at 0.25 mm and 
0.5 mm, respectively (0.25 mm corresponds to 1-nm band path). For each sample, 100 μL 
solutions were transferred into a square quartz cell. All samples were excited at 294 nm and 
the emission spectra were collected from 320 to 650 nm. A standard sample (2mM ellipticine 
in ethanol, sealed and degassed) was used in each run to correct the lamp intensity variations. 
The fluorescence intensity I at 520 nm and standard fluorescence intensity Is were obtained 
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by taking the average from 510 to 530 nm and from 424 to 432 nm (peak at 428 nm), 
respectively. 
3.5 1-Anilino-8-Naphthalene Sulfonate (ANS) Fluorescence Assay 
The fluorescence of probe ANS has been widely used in molecular self-assembly
103
. 
ANS solution (10 μM) was prepared in a phosphate buffer (10 mM) at pH 6. The fresh 
peptide solutions were mixed with equal volume of the ANS solution. A negative control was 
prepared by mixing ANS solution with pure water in the same way. The mixed solutions (80 
μL) were transfer to a quartz microcell and tested on the same spectrafluorometer above. For 
all concentrations, the fluorescence spectrum was obtained from 400 to 670 nm with the 
excitation at 360nm. The excitation and emission slit widths were set at 0.5 mm and 1.25 mm, 
respectively. To correct the lamp fluctuations, the spectra were normalized with light 
scattering of air at 360 nm. 
3.6 Circular Dichroism  
Secondary structure of arginine-rich ionic-complementary peptides and the peptide-EPT 
complexes were obtained on a J-810 Spectropolarimeter (Jasco, USA). A CD spectrum were 
acquired in the 190-270 nm wavelength range from samples in a 200 μL, 3 mm path length 
quartz cuvette at 25℃ at 200 nm/min with a response time of 2 s and pitch of 1 nm. All 
spectra shown were corrected by subtracting the baseline and were expressed as the average 
of three replicates.  
  50 
3.7 Dynamic Light Scattering (DLS) and Zeta potential 
The hydrodynamic diameter and surface charge of peptide assemblies (0.5 mg/mL) and 
peptide-EPT complexes (0.5:0.1 mg/mL) were investigated by Dynamic Light Scattering 
(DLS) and Zeta potential by Laser Doppler Velocimetry (LDV) on a Zetasizer Nano ZS 
(Malvern Instruments, Worcestershire, U.K.) equipped with a 4 mW He-Ne laser operating at 
633 nm. All measurements were performed at a measurement angle of 173° at 25℃. The 
intensity-based size distribution was obtained with the multimodal algorithm CONTIN, 
provided in the software package Dispersion Technology Software 5.0 (Malvern Instruments, 
Worcestershire, U.K.). Three measurements of at least 10 runs per measurement were tested 
to generate a size distribution plot based on intensity. The size and Zeta-potential were 
presented as mean value ± standard deviation. 
3.8  EPT Maximum Suspension Measurement 
The EPT maximum suspension in the peptide-EPT complexes was determined by EPT 
UV-absorption as published in our previous paper
39
. A calibration curve was obtained from 
the linear fitting of EPT absorption at a wavelength of 295 nm as a function of EPT 
concentration (1 10-3-1 10-2 mg/mL) prepared in a mixture of 95% DMSO with 5% water. 
The peptide-EPT complexes solution (0.5:0.1 mg/mL) was diluted in DMSO until within the 
range of calibration curve. 100 μL of the solution was transferred to a quartz microcell with a 
1 cm light path and tested on a UV-vis spectrophotometer (Agilent 8453 UV-vis 
spectroscopy). The value of EPT maximum suspension was averaged from three 
measurements, presented as mean value ± standard deviation.  
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The EPT maximum suspension was defined as the ratio of the mass of the suspended 
EPT to the mass of the EPT added for complex preparation using the following equation:  
                        
                       
                                           
       
 
 
3.9 Atomic Force Microscopy (AFM) 
Dimension Icon
R
 AFM (Bruker Nano Surfaces, Santa Barbara, CA) was employed to 
study the morphology and dimensions of peptide assemblies and peptide-EPT complexes. 
The samples were prepared by depositing the peptide/complexes suspensions (50 μL) on a 
freshly cleaved mica surface for 10-30 min, followed by washing 3 times with 50 μL pure 
water to remove unattached samples. After drying at room temperature overnight, AFM 
imaging was performed using PeakForce QNM mode. All images were acquired a silicon 
nitride tip (type SCANASYST-AIR, Bruker) with a typical tip radius of 2 nm and frequency 
of 70 kHz. The images with a scan size of 2 2 μm2 were used.  
3.10 Transmission Electron Microscopy Imaging 
Transmission electron microscopy was performed with a Philips CM20 electron 
microscope (Philips Electronics Ltd. Guildford, U.K.) at an accelerating voltage of 200kV. 
Images were digitalized using a Gatan 679 slow-scan CCD camera and analyzed using 
DIGTALMICROGRAPH (version 2.1, Gatan Inc. Pleasanton, CA). 10 μL of peptides or 
peptide-ellipticine complexes solution was incubated on 1 400-mesh carbon-coated Formvar 
copper grid (Marivac Ltd., St. Laurent, QC) for 15 min. Excess solution was drawn off the 
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edge of the grid with tissue paper. 10 μL of 2% (w/v) uranyl acetate was used to staine the 
grid for 10 s. Excess stains were drawn off again, and the grid was air-dried before TEM 
imaging.  
3.11 Cellular Toxicity Tests (MTT and CCK8) 
Two cancer cell lines, human lung carcinoma cell line A549 and breast cancer cell line 
MCF-7, were used for the cellular toxicity tests on the peptide-EPT complexes. A549 and 
MCF-7 were cultured in F12 containing 10% FBS and MEM containing 10% FBS and 0.1% 
insulin, respectively. Both of them were grown at 37℃ in a humidified incubator (with 5% 
CO2). When the cells were  95% confluent, they were rinsed once with PBS, followed by 
trypsinized and suspended in culture medium. After centrifuging at 500 rcp for 5 min, the 
cell pallets were resuspended in fresh cell culture media at concentrations of 5 104 and 
1 105 cells/mL for A549 and MCF-7, respectively. For each type of cell, the cell 
suspensions (200 μL) were seeded into each well of a clear, flat bottom, 96-well plate (Costar) 
and incubated for 24 h. The old media were replaced with fresh culture media (150 μL) 
followed by an addition of treatments (50 μL) into each well, resulting in a 4-fold dilution of 
the treatments. The plates were incubated for another 24 h prior to performing the cell 
viability assay. 
MTT assay or CCK-8 assay were used to determine the cell viability after each 
treatment. The detailed procedure was described in our previous publications
21
. 
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Chapter 4 
Results and Discussion 
4.1 Basic Design Principals of Arginine-Rich Ionic Complementary Peptides as 
Protonated EPT Delivery Carrier 
An anticancer drug ellipticine (EPT) has long been known for its significant anticancer 
and anti-HIV activities
31
. However, its poor aqueous solubility, severe side effects and low 
bioavailability constitutede major obstacles toward its medical deployment
33
. Recently, EPT 
has drawn renewed attention as new drug delivery technologies have emerged
17, 21, 35, 104
. It 
was found that EPT has three different molecular states: neutral, crystalline and protonated 
(Figure 4.1). Among the three molecular states, protonated EPT draws our attention because 
it has higher anticancer activity than the other two states
21, 39
. Although EPT delivery carrier 
has been widely studied; the specific delivery carrier could encapsulate prescribe protonated 
EPT molecules still has not been reported. Therefore, it is necessary to develop a new drug 
nanocarrier that could deliver protonated EPT and keep good cytotoxicity upon dilution in 
aqueous solution to maximize drug therapeutic effects.  
 
Figure 4.1 Different Forms of Ellipticine 
The family of self-assembling peptide EAK16s has been extensively studied in our 
group as a novel and promising biomaterial for constructing drug delivery carriers. This 
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unique self-assembling ionic complementary peptide was utilized to encapsulate hydrophobic 
EPT through strong hydrophobic interaction
21, 105
.  By forming β-sheet rich nanofiber 
networks, EAK16-II could provide a protective microenvironment to stabilize not only 
microcrystal EPT, but also protonated EPT by increasing the peptide-to-EPT ratio (>5:1 by 
mass). Further studies showed that protonated EPT had a faster transfer rate than that of 
crystalline EPT from the peptide-EPT complex to EPC vesicles
21
. In vitro cytotoxicity 
studies also indicated that the complexes with protonated ellipticine were more effective at 
killing cancer cells. However, the stability of EAK16-II-EPT complexes in relation to its 
anticancer activity was not very good upon dilution. The cellular toxicity (>60% cell viability) 
decreased quickly after 16 times dilution of the complexes. In a recent study, a molecular 
binding model with electrostatic interaction as the primary intermolecular force between the 
negatively charged glutamic acids in EAK16-II and protonated EPT has been proposed
39
. In 
this model, we assume that one protonated EPT molecule would bind to only one 
deprotonated carboxylate of glutamic acid in EAK16-II. There are four glutamic acids in one 
EAK16 molecule, in theory, could attract four pronated EPT molecules, while the positively 
charged lysines may render the EAK-EPT complex to be positively charged overall. The EPT 
loading capacity in EAK demonstrated that each mg of EAK could stabilize about 0.42 mg 
EPT in slightly acidic environments, which is significantly higher that the usual loading 
capacity of other carrier systems. 
If we altered the charge distribution on the peptide sequence (EAK16-II: --++--++ vs. 
EAK16-IV: ----++++), no obvious difference have been observed both on the complex 
formation and molecular state of EPT in the complex
105
. On the other hand, EFK16-II, a 
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more hydrophobic residue F replacing A in EAK16-II, stabilized neutral EPT molecules and 
microcrystalline EPT instead of protonated EPT. One possible explanation to this 
phenomenon is because the benzene ring of phenylalanine may hinder the possibility of its 
neighbor negatively charged carboxyl group to interacting pyridine-like nitrogen atoms of 
EPT. In vitro studies proved that EFK16-EPT complexes possessed lower cellular toxicity 
against cancer cells than EAK16-EPT complexes, but it exhibited good stability upon 
dilution in water due to a possible stronger hydrophobic interaction between peptide and 
neutral EPT and microcrystalline EPT.   
Based on our previous experience, we properly design a series of new peptides which 
may strengthen the interaction between peptide and protonated EPT and provide better 
encapsulation efficiency. A small library of model peptides, EAR8-II, EAR8-a, ELR8-a and 
EAR16-II were designed by systematically altering EAK16 with different length, sequence 
and hydrophobicity, as shown in Figure 3.1 and Table 4.1.  
Table 4.1 Library of novel arginine-rich ionic complementary peptides 
Peptide name # of Amino Acid Sequence (n-c) 
EAR8-II 8 n-AEAEARAR-c 
EAR8-a 8 n-AAEEAARR-c 
ELR8-a 8 n-LLEELLRR-c 
EAR16-II 16 n-AEAEARARAEAEARAR-c 
 
Here we chose arginine (R) to replace lysine (K) because of the following reasons. First, 
the side chain of arginine has higher pKa value than lysine. With a pKa of 12.48, the 
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guanidinium group is positively charged in acidic, neutral and even more basic environment, 
which means it can create stabilizing hydrogen bonds even in a slightly basic environment
106
. 
Hydrogen bonding between the guanidinium group and the pyridine-like nitrogen atoms of 
EPT could induce electron redistribution and stabilize the protonated EPT, which is the 
prescribed state we need. Second, the guanidinium group has two amino groups, which 
allows the formation of hydrogen bonding from two directions.  Third, arginine-rich 
peptides have shown strong cell-penetrating ability through molecular recognition of the 
guanidinium/phosphate pair. The hydrogen bonding between guanidinium moiety and 
phosphate group may facilitate arginine rich peptides penetrate the cell membrane 
efficiently
107
. Overall, these special advantageous properties of arginine over lysine make it 
possible for arginine rich ionic complementary peptide to be used as an ideal biomaterial to 
stabilize protonated EPT quickly and encapsulate more drugs. The theoretical model for the 
mechanism of interaction between arginine rich ionic complementary peptide and protonated 
EPT was depicted in Figure 4.2. 
Since residue Phenylalnine (F) may be too hydrophobic to encapsulate protonated EPT, 
less hydrophobic residue Leucine (L) was chosen to replace residue Alanine (A) of EAR. 
Such a slightly change in hydrophobicity may alter the microenvironment surrounded around 
EPT and lead to different states of EPT molecule. And also, peptide length was changed from 
8 amino acids to 16 amino acids to investigate the length effect on peptide assemblies and 
their complexation with EPT. 
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Figure 4.2 Theoretical model for the mechanism of interaction between peptide and protonated 
EPT. 
In the next part, the self-assembly property of the peptides was characterized by 
Axisymmetric Drop Shape Analysis-Profile (ADSA-P) technique and 
1-anilino-8-naphthalene sulfonate (ANS) fluorescence assay. Their potentials in drug 
delivery application were explored, the fluorescence technique was utilized to characterize 
the molecular state of EPT in the complex to see if the prescribed protonated EPT can be 
encapsulated in the peptide self-assembly, and UV technique was used to determine the EPT 
encapsulation efficiency of peptide-EPT compelxes. Then the effects of length (EAR8-II vs. 
EAR16-II), sequence (EAR8-II vs. EAR8-a) and hydrophobicity (EAR8-a vs. ELR8-a) on 
peptide self-assembly and peptide-EPT complexes were studied in details for their secondary 
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structure, particle size distribution, surface charge, and morphology. The cytotoxicity of the 
peptide and peptide-EPT complexes was tested in vitro against two cancer cell lines: 
non-small cell lung cancer cell A549 and breast cancer cell MCF-7. The stability of the 
complexes upon serial dilutions in aqueous solution was further investigated in relation to 
anticancer activity. Information obtained in this study is aimed at providing appropriate 
design principles for selecting peptide sequences and length, to construct advanced functional 
peptide carriers for anticancer drug delivery. 
4.2  Self-Assembly Ability of Peptides and Their Potentials to Encapsulate 
Protonated EPT 
The self-assembly ability of peptides were first studied. Critical aggregation 
concentration (CAC) was measured to evaluate the self-assembly strength by ADSA-P and 
1-anilino-8-naphthalene sulfonate (ANS) fluorescence assay. For ELR8-a and EAR16-II, The 
surface tension of peptides solution decreased with increasing peptide concentration, and 
then reached to a plateau (Figure 4.3 a, b). This profile could be simply fitted with two 
straight lines: one for the decline region and the other for the plateau. The intersection of the 
two lines indicated the CAC of 51.15 μM and 30.40 μM for ELR8-a and EAR16-II, 
respectively. For EAR8-II and EAR8-a, the surface tension of peptide solutions showed no 
tendency in relation to the peptide concentration, which means there was no CAC can be 
obtained. This result was further confirmed by the ANS fluorescence assay as shown in 
Figure 4.3 c and d, where the ANS fluorescence intensity and peak (at 520 nm) remained 
unchanged in the range of peptide concentration from 0 to 600  M, indicating there are no 
hydrophobic binding sites detected among the test peptide concentrations. It is worth noting 
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that EAR16-II has a double length (16 amino acids) in the sequence compare to EAR8-II and 
EAR8-a. It explains the effect of length on the peptide self-assembly ability, the long length 
can provide more interactions for peptide association
102
. In addition, ELR8-a has more 
hydrophobic L residue, is believed to have a much stronger hydrophobic interaction than 
EAR8-a and EAR8-II. This comparison shows that longer length (EAR16-II vs. EAR8-II and 
EAR8-a) and more hydrophobic residues (ELR8-a vs. EAR-a) in the sequence indeed 
enhance the peptide self-assembly ability, whereas the effect of sequence (EAR8-II vs. 
EAR8-a) shows no difference regarding to short peptides. The low CAC may strengthen the 
association between peptide and hydrophobic drug under extensive dilution in biological 
systems.  
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Figure 4.3 The critical aggregation concentration (CAC) of ELR8-a and EAR16-II was 
determined by a, b) surface tension. c, d) ANS fluorescence binding assay was used to determine 
the hydrophobicity of EAR8-a and EAR8-II assemblies. The CAC was found to be 51.15 μM 
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and 30.40 μM for ELR8-a and EAR16-II, respectively. The legend in (c, d) indicates the peptide 
concentration ranging from 0 to 600 μM. 
From our previous studies, the peptide-EPT complex formation in water is peptide 
concentration-dependent. With a combination of 0.1 mg/mL EPT and 0.5 mg/mL peptide, 
only EAK16-II can stabilize protonated EPT in the complex
105
. The converted molar ratios 
between EPT to anionic amino acid E is 1:3, indicating there are more than enough glutamic 
acids to bind all of the protonated EPT. Here we borrow the 5:1 mass ratio of peptide to EPT 
to investigate the molecular state of EPT in the complex formation by fluorescence 
spectrometer. In this case, the molar ratio of EPT to E are 1:2.5, 1:2.3, 1:2.6 for EAR8, 
ELR8-a and EAR16, respectively. As expected, for all four peptides, the fluorescence 
spectrum exhibited a characteristic of protonated EPT with a peak at 520 nm after 24 h 
stirring, as shown in Figure 4.4. The peak at 520 nm initially went up and reached the 
maximum at 4 times of dilution, this phenomenon might be caused by the inner filter effect 
(IFE) as indicated in our earlier publication
39
. Then the intensity came down gradually due to 
the decreased EPT dose upon dilution. Note that even after 4000x dilution, there was no 
crystalline EPT (468 nm) and neutral EPT (440 nm) were traced. These results proved our 
theory that the complexes have relatively good stability which can stand upon extensively 
dilution.  
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Figure 4.4 The fluorescence spectra of the peptide-ellipticine complexes upon serial dilution for 
EAR8-II, EAR8-a, ELR8-a and EAR16-II, respectively. The stock solutions were prepared with 
0.5 mg/mL peptide and 0.1 mg/mL EPT. Inset indicates the spectra of the complexes upon 1000 
to 4000 times dilution.  
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In addition, even though EAR8-II and EAR-a don’t have a specific CAC, fluorescence 
study showed that these two peptides could interact with protonated EPT and stabilized it to 
the same extent as ELR8-a and EAR16-II. It may be explained by the molecular binding 
model proposed in the previous part, as shown in Figure 4.2. More importantly, it is believed 
that the good dilution stability of the complex will further affect its therapeutic efficiency in 
biological system. 
EPT maximum suspension was determined by UV-vis spectrometer. A standard 
concentration calibration curve was obtained from the linear fitting of EPT absorption at a 
wavelength of 295 nm as a function of EPT concentration, as shown in equation (1).  
                                                                                                      
(1) 
Where y is the absorbance value and x is the EPT concentration. The calibration curve 
for the absorbance of EPT was linear over the range of standard concentration EPT at 
1 10-3-1 10-2 mg/mL with a correlation coefficient of R2 = 0.9954 (Figure 4.5). 
With a combination of 0.1 mg/mL EPT and 0.5 mg/mL peptide, all four peptide-EPT 
complexes show great maximum suspension (~100%), as shown in Table 4.2. It verifies our 
theory that there is more than enough peptide to bind with protonated EPT in the systems at 
the 5:1 mass ratio of peptide to EPT. 
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Figure 4.5 Standard curve from the linear fitting of EPT absorption at a wavelength of 295 nm 
as a function of EPT concentration. 
Table 4.2 Characterization of peptide-EPT complexes 
Nanoparticle Mean size (nm)
a
  Polydispersity  
index 
Zeta potential 
(mV)
a
 
Maximum 
suspension (%)
a
 
EAR8-II 336.7±27.5 0.450 7.4 4.9 - 
EAR8-a 205.6±16.3 0.487 17.3±5.0 - 
ELR8-a 365.2±14.5 0.669 14.5±6.7 - 
EAR16-II 199.7±2.69 0.667 43.3±5.0 - 
EAR8-II-EPT 212.0±1.89 0.253 51.0±10.4 101.1±0.4 
EAR8-a-EPT 222.1±9.53 0.319 48.6±9.6 99.3±0.3 
ELR8-a-EPT 116.4±4.59 0.278 43.3±6.2 109.9±0.6 
EAR16-II-EPT 174.2±0.24 0.317 59.8±10.4 110.0±1.0 
a
 Value reported as mean ± S.D. (n=3) 
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4.3  Length and Sequence Effect on the Peptide Assemblies and Complex 
Formation 
So far, we have shown that peptide sequence, length and hydrophobicity will affect the 
peptide self-assembly property and its potential in encapsulating protonated EPT in water. 
Such effects may further influence the physiochemical properties of complex, such as 
particles size, surface charge and morphology, which will have effect on the anticancer 
activity and pathway of cellular uptake for nanoparticles
10, 108
.  
Secondary structure 
The secondary structure of peptides in the absence and presence of EPT were 
characterized by circular dichroim (CD) spectroscopy. Spectra were collected at 0.5 mg/mL 
peptide with or without 0.1 mg/mL EPT. As reported in Figure 4.6, the two short peptides, 
EAR8-II and EAR8-a, presented almost the same CD spectra in pure water characterized by 
a strong negative band at 197nm and a weak negative band of approximately equal intensity 
near 222nm, suggesting the presence of a mixture structure of random coil and α-helix. The 
CD spectra of ELR8-a exhibited similar trend with EAR8-a except a weak positive band near 
192nm, it corresponds a mixture structure of random coil and high level of α-helix. In 
contrast, the CD spectra for EAR16-II, produced a strong positive band at 197nm and 
negative band around 217nm, indicative of β-sheet formation. The identical nature of the CD 
profiles clearly indicates that the presence of EPT molecules during self-assembly of peptides 
do not hinder their original secondary structures.  
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Figure 4.6. CD spectra of 0.5 mg/ml peptide solution (A) and complex of 0.5 mg/ml peptide with 
0.1 mg/mL EPT (B). The CD measurement indicated that (A) EAR8-II, EAR8-a and ELR8-a 
exhibited a mixture structure of random coil and α-helix, whereas EAR16-II forms β-sheet 
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structure, (B) The identical nature of the CD profiles clearly indicates that the presence of EPT 
molecules during self-assembly of peptides do not hinder their original secondary structures. 
Size ditribution and Surface charge 
Ideal nanoparticles encapsulating drug should meet the following requirements: (i) 
particle size < 200 nm to facilitate passive targeting to solid tumors via the enhanced 
permeability and retention (EPR) effect
109
; (ii) high positive Zeta-potential to increase 
interaction with negatively charged cell surface
110
. The size distribution of the peptide 
assemblies and peptide-EPT complexes were characterized by measuring the hydrodynamic 
diameter at a peptide concentration of 0.5 mg/mL, EPT concentration of 0.1 mg/mL. It is 
clearly seen that these four peptide assemblies have a broad size distribution from 1 nm to 10 
μm and had several size populations. The peptides alone are very polydispersed and over the 
detection limit of the instrument (Table 4.2). When the EPT was introduced to the peptide 
aqueous solution, the size distributions of complexes change significantly as shown in Figure 
4.7. An average diameter of ~ 100 to 200 nm was obtained. The significantly change of size 
distribution indicates peptide assemblies interact with EPT to form a more compact and 
smaller nanoparticles, which may be ideal for passive targeting to solid tumors via the 
enhanced permeability and retention effect
12
.  
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Figure 4.7 Size distributions of peptide self-assemblies and peptide-EPT complexes 
Zeta potential, related to both surface charge and the local environment of the particle, 
might be a critical parameter for cellular interaction. Zeta potential values obtained for three 
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short peptides are quite similar, with values less than +20 mV as shown in Figure 4.8, which 
indicates the short peptide assemblies have poor colloidal stability. A value of +43.3±4.98 
mV was obtained for EAR16, showed better stability than the short peptides. Since EPT is 
stabilized in protonated form in the peptide-EPT complexes, it is expected to be positively 
charged. Zeta potential measurements of complexes confirmed our prediction, the values for 
all peptide-EPT complexes increased to more than +40 mV, which can be considered as an 
excellent stable system. 
 
Figure 4.8 Zeta potential of peptide and peptide-EPT complex 
Morphology  
Atomic Force Microscopy (AFM) and Transmission Electron Microscopy (TEM) were 
used as complementary methods to study the morphology of peptide assemblies and 
peptide-EPT complexes. Figure 4.9 shows AFM and TEM images of these peptides and their 
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complexes with EPT in aqueous solution at a peptide concentration of 0.5 mg/mL and EPT 
concentration of 0.1 mg/mL. From AFM images, it is clearly seen that both EAR8-II and 
EAR8-a have a mixture structure of amorphous assemblies and short straight fibers (Figure 
4.9 A-i and C-i). The dimentions of these two peptides assemblies are similar, range from 
25-40nm (amorphous assemblies) to 100-200 nm (fibril assemblies) with same height of 1 
nm. Their complexes with EPT tend to have amorphous assemblies with a radius of 60-90 
nm and a height of 10 nm, while three or four globules may aggregate together to form a big 
amorphous assemblies (Figure 4.9 B-i and D-i). In the case of ELR8-a, similar amorphous 
assemblies as EAR8-II and EAR8-a are formed in the absence of fibril nanostructures 
(Figure 4.9 E-i); while the introduction of EPT may bind a few peptides together to form big 
globules with a radius of 200 nm (Figure 4.9 F-i). For the assemblies of EAR16-II, flat and 
straight nanofiber structures were observed; larger numbers of crosslinking points were seen 
in Figure 4.9 G-i, with width distributed from 20 nm to 30 nm and length in micrometers. On 
the other hand, it was shown that a region of both elongating and thickening fibrillar bundles 
coexisted with isolated fibrils in the EAR16-EPT complexes system, suggesting that peptide 
was more than enough to encapsulate EPT molecules.  
Transmission electron microscopy was used to confirm the morphology results obtained 
from AFM imaging. For both EAR8 peptides, fibrillar assemblies disappeared to leave 
amorphous assemblies alone, which is different from AFM images. In the case of ELR8-EPT 
complexes, small globular structures with a radius of 50 nm are clearly seen compare with 
big globules of AFM image.  
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Figure 4.9 AFM and TEM images of EAR8-II (A-i, A-ii), EAR8-II-EPT complexes (B-i, B-ii), 
EAR8-a (C-i, C-ii), EAR8-a-EPT complexes (D-i, D-ii), ELR8-a (E-i, E-ii), ELR8-a-EPT 
complexes (F-i, F-ii), EAR16-II (G-i, G-ii), and EAR16-II-EPT complexes (H-i, H-ii). Scan area 
is 2 μm×2 μm for AFM images. Scale bar is 100 nm for TEM images. 
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4.4 Cellular Toxicity of Peptide-EPT Complexes and their dilutions 
So far, we have shown that these four peptides can solubilize and stabilize protonated 
EPT in aqueous solution. It has been reported that the protonated EPT is more effective at 
killing cancer cells than other two states of EPT (neutral and crystalline form). This may due 
to two reasons: (1) protonated EPT tends to bind with negatively charged cell membranes, 
and accumulate at the membrane surface; the hydrophobic moiety of EPT further helps it 
cross the cell membrane
105
. (2) fast release kinetics of protonated EPT from the complexes
21
. 
To gain more insight concerning the differences in these four peptide-EPT complexes, the 
cellular toxicity against two cancer cells, MCF-7 and A549, and the stability of the 
complexes in relation to anticancer activity upon dilution in water were studied. The 
complexes stability is a crucial factor in determining its applicability in later animal studies 
and preclinical experiments.  
Figure 4.10 shows the cell viability of two cancer cell lines, A549 and MCF-7, upon 
treatments with control samples and complexes after 24 h. Comparing to the negative control 
(no treatment), the solvent (water) and four peptides controls had minor toxicity to the cells 
(90-95% viability), suggesting that the four peptides alone were non-cytotoxic. The drug 
control (0.1 mg/mL EPT) caused 20-30% more cell death in comparison with the solvent 
control, whereas all complexes showed great potency in both cancer cells killing than EPT 
alone in pure water, leading to nearly zero cell viability. This could be a result of peptide 
stabilizing more protonated EPT in solution.   
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Figure 4.10 Cellular toxicity of the peptides and their complexes with EPT for A549 and MCF-7 
cells. The viability of non-treated cells is a (M: cells were treated with culture medium.) For the 
solvent control, cells were treated with pure water; for the drug control, cells were treated with 
EPT in pure water with the absence of peptides. Blue bars represent the peptide controls where 
no ellipticine was added. 
Previous fluorescence study has implied that the complexes dilution stability was very 
good resulting from strong association between EPT and peptide assemblies, we then 
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proceeded to investigate the dilution stability of peptide-EPT complexes in relation to the 
cellular toxicity in aqueous solution. Figure 4.11 shows the cellular toxicity of the complexes 
with 0.5 mg/mL EAR8-II, EAR8-a, ELR8-a and EAR16-II upon serial dilution in water 
against both cell lines. For A549 cells, the cell viability is very low and less than 2% with 
these four complexes even at 10 times dilution, gave much stronger cytotoxicity than 
complex formulated with EAK16 at the same concentration, which was not effective at 
killing cancer cells after 4 times dilution
105
. After 10 times dilution, cell viability of A549 
cells was gradually reduced in a dose-responsive manner. Similar results were observed in 
MCF-7 cell lines, with the low cell viability after the same treatment (less than 5%) except 
for in the case of 10 times dilution (20-30%). However, the cell viability increased sharply 
upon the following serial dilution. These results may due to the decrease concentration of 
EPT during serial dilution. To further investigate the cytotoxicities of complexes, the IC50 
values were estimated from Figure 4.11 and have been listed inTable 2.1. On the basis of the 
calculated IC50, complexes with EAR8-II, EA8-a and ELR8-a showed similar efficacy at 
killing both cancer cells with slight differences. In the case of EAR16-EPT complex, the 
cytotoxicity against MCF-7 is much lower than against A549 by comparing the IC50 values. 
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Figure 4.11 Cellular toxicity of the complexes formulated with four peptides at a peptide 
concentration of 0.5 mg/mL and 0.1 mg/mL EPT and their serial dilutions in water for 
A549 cells (A) and MCF-7 cells (B). 
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Table 4.3 Cytotoxic activities of peptide-EPT complexes  
Nanoparticles 
Cytotoxicity assay (IC50,  M) 
Lung Cancer 
(A549) 
Breast cancer 
(MCF-7) 
EAR8-II-EPT 4.26 0.62 10.68 1.09 
EAR8-a-EPT 3.16 0.35 4.41 0.40 
ELR8-a-EPT 5.04 0.98 6.19 1.46 
EAR16-II-EPT 0.36 0.12 18.90 0.46 
 
This result seems to contradict to the already known fact that protonated EPT is more 
effective at killing MCF-7 cells. However, the reason behind this phenomenon is still unclear. 
Two potential factors are speculated that may cause the huge different therapeutic efficacies 
of EAR16-EPT for A549 and MCF-7. First, when culturing in vitro, MCF-7 cell line is 
capable of forming small domes while A549 grows as a monolayer. In the case of short 
peptide-EPT complex, both cancer cells are exposed to the sub-micron amorphous 
nanoparticles, which increase the opportunity of nanoparticles to attach and penetrate through 
the membrane surface of cancer cells. However, the dome of MCF-7 may hinder the long 
fibers of EAR16-EPT to attach to the membrane surface of cancer cells buried inside, 
causing lower cytotoxicity. By contrast, A549 monolayer exposes every cells outside, which 
allows the EAR16-EPT fibers to attack each cancer cells, enhanced the cytotoxicity of 
complex since the long fibers may encapsulate more protonated EPT. Second, it has been 
reported the membrane surface constitute of A549 and MCF-7 are different. The high 
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cholesterol content of MCF-7 membrane decreases the membrane fluidity, which may inhibit 
the uptake of drugs compare with other cancer cells
111
.  
The cytotoxicity study presented above demonstrates that arginine-rich 
ionic-complementary peptides, EAR8-II, EAR8-a, ELR8-a and EAR16-II, can stabilize the 
prescribed protonated EPT in aqueous solution. The combination of 0.5 mg/mL peptide and 
0.1 mg/mL EPT exhibits excellent cancer inhibition efficacies and good stability upon 
dilution. Note that EAR16-EPT complex has a selective targeting to A549 cancer cell, which 
is important in the next phase studies on the peptide-based delivery of EPT in vivo. 
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Chapter 5 
Conclusion and Recommendation  
5.1 Conclusion 
This thesis explored the capability of arginine-rich ionic complementary peptides as a 
promising potential carrier for protonated ellipticine delivery. The thesis includes the 
following four parts: (i) Illustrating basic design principals of arginine-rich ionic 
complementary peptides; (ii) Studying self-assembly ability of peptides and potential to 
encapsulate protonated EPT; (iii) Investigating effect of length and sequence on the peptide 
assemblies and complex formation; (iv) Studying cellular toxicity of peptide-EPT complexes 
and their dilutions. The original contribution and conclusion for each part are presented in the 
following.  
A small library of model peptides, EAR8-II, EAR8-a, ELR8-a and EAR16-II were 
designed by systematically altering EAK16-II. Here we chose arginine (R) to replace lysine 
(K) because of the following reasons. (i) the side chain of arginine has higher pKa value than 
lysine. (ii) arginine’s guanidinium group also could interact with nearby aromatic ring of 
EPT via π-stacking. (iii) arginine-rich peptides have shown strong cell-penetrating ability 
without requiring a specific binding site. These special advantageous properties of arginine 
over lysine make it possible for arginine rich ionic complementary peptide to be used as an 
ideal biomaterial to stabilize protonated EPT quickly and encapsulate more drugs.  
5.1.1 Charge distribution and hydrophobicity effect of peptide 
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Table 5.1 Charge distribution effect of peptide on physicochemical properties and in vitro 
therapeutic effect of peptide and their complexation with EPT.  
 
Table 5.2 Hydrophobicity effect of peptide on physicochemical properties and in vitro 
therapeutic effect of peptide and their complexation with EPT. 
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For short peptides, EAR8-II, EAR8-a and ELR8-a, increase in peptide hydrophobicity 
indeed enhances the peptide self-assembly ability. The surface tension of EAR8-II and 
EAR8-a peptide solutions shows that there is no relationship between surface tension and the 
peptide concentration. The ANS fluorescence assay further confirms the results. While 
ELR8-a, more hydrophobic amino acid leucine increases the hydrophobicity of peptide, a 
CAC of 51.15 uM is obtained. However, the improved surface property of ELR8-a does not 
enhance its capability to encapsulate EPT. At a concentration of 0.5:0.1 mg/mL (peptide to 
EPT), fluorescence spectrum indicates that all three short peptides can solubilize and 
stabilize EPT in protonated form upon dilution to same extent, which means charge 
distribution and hydrophobicity effect will not have much effect on their complexations with 
EPT. 
Further studies on physicochemical properties and In vitro therapeutic efficacies of 
peptide and peptide-EPT complexes indicate that both slight charge distribution and 
hydrophobicity difference will not affect peptide’s complexation with EPT and their 
anticancer activity.  One possible explanation is because the length of 8 amino acids peptide 
is too short to exhibit such a slight difference in charge distribution and hydrophobicty.  
Comparison between short length peptides and long length peptide confirms it in the next 
section. Length effect is more significant than charge distribution and hydrophobicity effects. 
5.1.2 Length effect  
Length effect of peptide is apparently the most significant effect on peptide assemblies 
and their complexation with EPT. First of all, longer length of EAR16 can provide more 
peptide association than short length peptides, resulting in better surface properties with a 
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CAC value of 30.40 uM.  Second, EAR16 forms β-sheet rich nanofibers instead of 
amorphous nanostructures of short length peptides.  Third, the anticancer activity of 
EAR16-EPT complex against A549 is much stronger than other peptides with a lower IC50 
value, which is important in the next phase studies on the peptide-based delivery of EPT in 
vivo.  
Table 5.3 Length effect of peptide on physicochemical properties and in vitro therapeutic effect 
of peptide and their complexation with EPT. 
 
Overall, slight charge distribution and hydrophobicity difference of 8 amino acids 
peptide will not have much effect on peptide assemblies and their complexation with EPT; 
whereas increase in peptide length could strengthen the interaction between peptide and EPT, 
which gives the stronger anticancer activity of EAR16-EPT to A549. In addition, replacing 
lysine in EAK16 with arginine indeed improves peptide’s complexation with hydrophobic 
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anticancer drug. This study provides information for selecting peptide sequence to construct 
advanced functional peptide-based delivery system. 
5.2 Recommendation 
Recommended future work to develop arginine-rich ionic complementary peptides as 
nanocarrier for prescribed protonated EPT delivery can be divided into four groups: (i) 
determine the aggregation number of peptide self assemblies and its complex with EPT; (ii) 
further study the mechanism behind EAR16’s selectivity targeting to A549; (iii) evaluation 
of the complexes in 3D cell culture; (iv) design new peptide library based on current peptide 
sequence. The detailed information is listed in the following: 
5.2.1 Determine the aggregation number of peptide assemblies and its complex with 
EPT 
Aggregation number is an important parameter to characterize the nanostructure of 
peptide assemblies and its complex with EPT. One method to obtain aggregation number is 
performing static light scattering technique. Based on the aggregation number results and 
AFM morphology images, we may have a clear idea of the nanostructure of peptide 
assemblies.  
                    
                                       
                                 
 
5.2.2 Further study the mechanism behind EAR16’s selectivity targeting to A549  
It has been found that the cellular uptake of a free drug may depend on membrane 
properties, in particular on cholesterol content which has been shown to have a high impact 
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on membrane stiffness and fluidity. Petra et al. have shown that the uptake of doxorubicin is 
enhanced if membrane fluidity is increased upon cholesterol depletion. The same protocol 
can be applied to our complexes to evaluate the impact of cholesterol content of cell 
membrane.   
5.2.3 Evaluation of the complexes in 3D cell culture  
In a further step towards clinical application, 2-dimensional cell culture may be replaced 
by 3-dimensional cell culture, whose physiology, morphology and nutrient supply is closer to 
the in vivo situation in tumors. Two major advantages of 3D cell culture technique are (i) 
increasing the accuracy of predicting complex in vivo drug interactions; (ii) decreasing the 
time and cost of drug development. Thus, the use of 3D culture techniques is an alternative 
approach to translate into better modeling of drug behavior on cancer cells.  
5.2.4 Design new peptide library based on current peptide sequence 
New peptides are designed based on our current research results. These peptides may 
possess higher encapsulation efficiency of drug and better stability.  
Peptide # of Amino Acids Sequence (n-c) Charge distribution 
EAR16-a 16 n-AAEEAARRAAEEAARR-c --++--++ 
ELR16-a 16 n-LLEELLRRLLEELLRR-c --++--++ 
ELR16-II 16 n-LELELRLRLELELRLR-c --++--++ 
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